
ABOUT CATALENT
Catalyst + Talent. Our name combines these ideas. As the world’s #1 drug development, delivery and supply partner with over 80 years of experience, we are the catalyst for your success. We have helped thousands of innovators by optimizing and manufacturing thousands of pharmaceutical, biologic, consumer health and beauty products utilizing our superior and innovative drug delivery technologies to improve their value to patients and consumers.
Catalent is a vibrant growing community of 8,500 global employees with the passion to unlock the potential of your product. Founded in 2007 as Catalent, our legacy of drug development goes much deeper, incorporating the inventions and innovations which have transformed the pharmaceutical industry. On July 30, 2014 Catalent announced its initial public offering and became a publicly traded on the New York Stock Exchange under the ticker symbol CTLT.
From early development to clinical supply and commercial manufacturing, our 30+ global site teams support you through all phases of development, delivery, and supply, accelerating your product’s path to market in segments such as pharmaceuticals, biologics, consumer health and beauty, and animal health utilizing our superior drug delivery technologies to improve therapeutic and product value to patients and consumers.
Whether you seek a single tailored solution or partnership through your product’s entire life cycle, we put our experience, expertise, and passion to work for you in unlocking the potential of your product.
ORAL CONTENT
CONTACT INFORMATION
Catalent
14 Schoolhouse Road
Somerset, NJ 08873
UNITED STATES
Phone: 877-587-1835
BIOLOGICS CONTENT
- Premier European Product Launch And Packaging Solution
- Secondary Packaging Strategies For Commercial Launch Of A Biologic
- Rapid Global Characterization Of Ig G1 Following Oxidative Stress
- High-Throughput Preformulation Development Platform For Biologics
- Analytical Quality By Design Using Design Of Experiments
- Strategies To Achieve Successful Approval & Launch
- Standardizing Process Characterization And Late Phase Development
- Characterization Of A Therapeutic mAb, Associated Antigen-Binding Fragments
- Intensified Fed-Batch Process Using N-1 Perfusion And ambr 15
- Ensuring Success In Early Biopharmaceutical Formulation Development
- Comparing Batch Versus Continuous Modes
- A Novel Purification Tool's Effects On HCP Reduction, Turbidity
- High-Throughput Formulation Development For High-Concentration mAbs
- Strategies For Process Characterization, Late Phase Development
- Achieving Unique Synergies In Antibody Expression
- Transitioning From Vial To Prefilled Syringe
CELL AND GENE CONTENT
- Process Validation: A Critical Step In A Biopharma Product's Lifecycle
- Cell & Gene Therapies – Changing The Healthcare Landscape
- 07.14.23 -- Accelerate Development Timelines With Improved Characterization Methods
- Exploring An Integrated Solution For AAV Vector Clinical Production
- Innovations In ADC Technologies
- UpTempo℠ AAV Platform Process
- Harnessing mRNA As A Readout To Develop Robust BioPotency Assays
- Process Optimization For mAb Commercial Manufacturing
- Streamline Process Characterization For Successful Validation Campaigns